PDF(Pubmed)
Abstract：
Adalimumab, an anti-tumor necrosis factor-α (TNF-α), is widely prescribed for many autoimmune diseases and chronic inflammatory skin diseases such as hidradenitis suppurative, psoriasis, etc. We report a case of lichenoid drug eruption secondary to adalimumab, a rare side effect, in a 62-year-old female with ulcerative colitis. The skin eruption appeared two weeks after initiating adalimumab. A skin biopsy was taken, and the histopathological findings correlated with a lichenoid drug eruption. Although rare, drug-induced lichen planus has been associated with adalimumab. Early recognition and a high index of suspicion are key in the prompt management of these cases. The discontinuation of adalimumab must be carefully weighed against its therapeutic benefits, as the discontinuation might trigger a severe form of inflammation in the primary autoimmune disease being treated. Extreme caution, early intervention, and a multidisciplinary approach are best for the overall well-being and optimal care of the individual.
摘要：
阿达木单抗,抗肿瘤坏死因子-α（TNF-α），广泛用于许多自身免疫性疾病和慢性炎症性皮肤病，如化脓性汗腺炎，牛皮癣,等。我们报告了一例继发于阿达木单抗的苔藓样药疹，一种罕见的副作用,一名62岁女性溃疡性结肠炎患者。开始阿达木单抗两周后出现皮肤爆发。做了皮肤活检,组织病理学发现与苔藓样药疹有关。虽然罕见，药物诱导的扁平苔藓与阿达木单抗相关.及早认识和高度怀疑是迅速处理这些案件的关键。停用阿达木单抗必须仔细权衡其治疗益处，因为停药可能会在正在治疗的原发性自身免疫性疾病中引发严重的炎症。极度小心，早期干预,多学科方法最适合个人的整体福祉和最佳护理。
